Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

盘后交易 07-22 18:26:47 EDT

183.03

-0.26

-0.14%

盘后185.36

+2.33+1.27%

18:24 EDT

最高185.40	最低180.11	成交量88.86万
今开180.66	昨收183.29	日振幅2.89%
总市值389.11亿	流通市值366.84亿	总股本2.13亿
成交额1.63亿	换手率0.44%	流通股本2.00亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":183.03,"timestamp":1784750400000,"preClose":183.29,"halted":0,"volume":888636,"hourTrading":{"tag":"盘后","latestPrice":185.3572,"preClose":183.03,"latestTime":"18:24 EDT","volume":21776,"amount":3997391.5756800002,"timestamp":1784759090950,"change":2.3272,"changeRate":0.012715,"amplitude":0.02027},"delay":0,"changeRate":-0.001418517104042724,"floatShares":200428539,"shares":212592561,"eps":-7.121384,"marketStatus":"盘后交易","change":-0.26,"latestTime":"07-22 18:26:47 EDT","open":180.66,"high":185.4,"low":180.11,"amount":163047270.96168,"amplitude":0.028861,"askPrice":186.74,"askSize":10,"bidPrice":183.17,"bidSize":220,"shortable":3,"etf":0,"ttmEps":-7.121384,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784764800000},"marketStatusCode":4,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":183.29,"preHourTrading":{"tag":"盘前","latestPrice":181.57,"preClose":183.29,"latestTime":"09:28 EDT","volume":985,"amount":180119.09955,"timestamp":1784726880023,"change":-1.72,"changeRate":-0.009384,"amplitude":0.016368},"postHourTrading":{"tag":"盘后","latestPrice":185.3572,"preClose":183.03,"latestTime":"18:24 EDT","volume":21776,"amount":3997391.5756800002,"timestamp":1784759090950,"change":2.3272,"changeRate":0.012715,"amplitude":0.02027},"volumeRatio":0.44724,"impliedVol":0.5622,"impliedVolPercentile":0.5179},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1178535518","title":"Revolution Medicines新药Daraxonrasib获FDA受理，用于既往治疗过的转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1178535518","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178535518?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:06","pubTimestamp":1784750800,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理Revolution Medicines, Inc.提交的新药上市申请（NDA），该申请旨在寻求批准其候选药物Daraxonrasib用于治疗既往接受过治疗的转移性胰腺癌患者。\n这一受理标志着该药物研发进程中的一个关键监管里程碑，意味着FDA已认定申请材料完整，并已启动实质性的审评流程。胰腺癌，尤其是转移性疾病，长期以来预后不佳，治疗选择有限，因此这一新疗法的审评进展备受业界关注。\n公司股价在消息公布后反应积极，市场正密切关注后续的审评时间表以及可能的批准前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","PTH","LU0109394709.USD","IDNA","BBH","RVMD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","CANC","BK4139","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0009354923.USD","LU0889565916.HKD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136893445","title":"异动解读｜Revolution Medicines盘前下跌5.11%，报172.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136893445","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136893445?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:32","pubTimestamp":1784277142,"startTime":"0","endTime":"0","summary":"7月17日，Revolution Medicines盘前下跌5.11%，报172.36美元/股，成交额4.49万美元。Revolution Medicines所在的生物科技行业中，个股中，艾伯维公司涨0.88%，吉利德科学涨0.72%，安进涨0.84%，福泰制药涨0.41%，再生元制药公司涨0.72%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症。公司核心管线daraxonrasib此前在转移性胰腺癌三期试验中展现显著总生存期获益，目前已进入EMA分阶段审评及FDA申报准备阶段，公司正积极搭建全球自主商业化团队。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175603747","title":"欧洲药品管理局启动分阶段审评，加速评估Revolution Medicines的Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=1175603747","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175603747?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:30","pubTimestamp":1783431047,"startTime":"0","endTime":"0","summary":"欧洲药品管理局已决定通过分阶段审评程序，加快对Revolution Medicines, Inc.（股票简称：RVMD）旗下在研药物Daraxonrasib的评估进程。此举旨在缩短该潜在疗法的审评时间，使其能更早惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BBH","IDNA","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","CANC","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","IE00BFTCPJ56.SGD","PTH","RVMD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155723179","title":"异动解读｜Revolution Medicines盘中上涨5.07%，ESMO GI数据亮眼叠加收入预期上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1155723179","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155723179?lang=zh_cn&edition=full","pubTime":"2026-06-30 03:39","pubTimestamp":1782761955,"startTime":"0","endTime":"0","summary":"6月30日，Revolution Medicines盘中上涨5.07%，报191.32美元/股，成交额7.69亿美元。消息面上，公司在欧洲肿瘤内科学会胃肠道肿瘤年会上披露最新临床数据，第二款RAS抑制剂zoldonrasib联合标准化疗在一线胰腺癌中客观缓解率达82%，zoldonrasib联合daraxonrasib的无化疗方案二线治疗ORR达50%，数据大超预期。此前瑞银指出，若双药联合数据积极，公司胰腺癌收入有望提升20%至40%，并预计daraxonrasib将快速获批上市。此外，公司已启动Rasolute 305三期试验患者治疗，进一步拓展一线治疗布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121703894","title":"Revolution Medicines启动Rasolute 305患者治疗，评估Zoldonrasib联合化疗作为Ras G12d转移性胰腺癌一线疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1121703894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121703894?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:00","pubTimestamp":1782216055,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. 已正式启动其名为Rasolute 305的三期临床试验的患者治疗工作。这项关键性研究旨在评估其候选药物Zoldonrasib与化疗联合方案，作为Ras G12d突变型转移性胰腺癌患者一线治疗的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","RVMD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167442691","title":"异动解读｜Revolution Medicines盘中下跌5.21%，报142.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167442691","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167442691?lang=zh_cn&edition=full","pubTime":"2026-06-10 23:23","pubTimestamp":1781104981,"startTime":"0","endTime":"0","summary":"6月10日，Revolution Medicines盘中下跌5.21%，报142.19美元/股，成交额1.28亿美元。Revolution Medicines所在的生物科技行业中，个股中，吉利德科学跌2.1%，Nuvalent涨0.1%，安进涨0.85%，艾伯维公司涨0.66%，Argenx SE跌0.06%。Revolution Medicines是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法，拥有基于结构的药物发现能力及针对RAS通路关键信号节点的深层管线。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113096257","title":"异动解读｜Revolution Medicines盘中下跌5.13%，ASCO大会胰腺癌数据利好兑现后股价高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1113096257","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113096257?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:39","pubTimestamp":1780411180,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中下跌5.13%，报153.18美元/股，成交额1.91亿美元。消息面上，此前ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，该数据同步发表于《新英格兰医学杂志》，被视为RAS靶向治疗里程碑突破。受此利好驱动，公司股价此前夜盘及盘前累计涨幅已超15%，奥本海默同步上调目标价至195美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105705147","title":"异动解读｜Revolution Medicines盘中上涨5.11%，ASCO大会胰腺癌III期数据大超预期持续提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1105705147","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105705147?lang=zh_cn&edition=full","pubTime":"2026-06-02 02:52","pubTimestamp":1780339963,"startTime":"0","endTime":"0","summary":"6月2日，Revolution Medicines盘中上涨5.11%，报165.445美元/股，成交额7.53亿美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。该数据首次将二线胰腺癌中位OS拉长至1年以上，被视为RAS靶向治疗的里程碑突破。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139903431","title":"异动解读｜Revolution Medicines盘前上涨15.38%，ASCO大会胰腺癌III期数据大超预期引爆市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1139903431","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139903431?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:02","pubTimestamp":1780300930,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines盘前上涨15.38%，报181.33美元/股，成交额43.73万美元。消息面上，ASCO大会集中展示公司核心品种daraxonrasib的III期RASolute 302研究完整数据，该研究入组500名既往接受过治疗的转移性胰腺导管腺癌患者。结果显示，daraxonrasib将总生存期从化疗组的6.6个月翻倍至13.2个月，无进展生存期从3.5个月延长至7.3个月，数据同步发表于《新英格兰医学杂志》。公司同步推进daraxonrasib一线治疗及联合用药试验，商业化前景持续扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127581925","title":"异动解读｜Revolution Medicines夜盘上涨7.95%，ASCO大会RAS抑制剂胰腺癌数据引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1127581925","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127581925?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272081,"startTime":"0","endTime":"0","summary":"6月1日，Revolution Medicines夜盘上涨7.95%，报170.0美元/股，成交额1.31万美元。消息面上，ASCO大会即将集中展示公司核心品种daraxonrasib的III期RASolute 302研究数据。胰腺癌长期被视为最难攻克的癌种之一，5年相对生存率仅约13%，该数据被视为RAS靶向治疗在胰腺癌领域的里程碑突破，ASCO正式报告在即，市场提前反映乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139383641","title":"谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139383641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139383641?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:36","pubTimestamp":1778236606,"startTime":"0","endTime":"0","summary":"根据最新提交的监管文件显示，Alphabet公司在截至2026年3月31日的季度内对其投资组合进行了显著调整。这家科技巨头披露持有PayPay公司310万份赞助存托凭证，同时增持Planet Labs Pbc公司10.4%的A类股份，使其总持股量达到3520万股。在金融领域，Alphabet报告持有芝加哥商品交易所约350万股股份。此外，Alphabet还披露持有Ethos Technologies公司380万份A类股份，同时将其在Revolution Medicines公司的持股比例削减1.6%，目前持有330万股。这些持仓变动均以2025年12月31日为基准进行对比。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1003077747.HKD","IE00B19Z8X17.USD","LU0107464264.USD","LU0511384066.AUD","SG9999000418.SGD","LU1674673691.USD","BK4576","LU2506952170.USD","LU1935043536.SGD","LU2756315664.SGD","LU0823434740.USD","LU2111349929.HKD","LU1670628061.USD","LU0553294199.USD","LU1989764748.USD","LU2271345857.HKD","LU1430594728.SGD","LU1261432733.SGD","SGXZ51526630.SGD","BK4534","LU1791710400.SGD","FULC","IE000BZT7R73.USD","BK4561","HK0000819398.USD","LU0823421416.USD","IE00B19Z3B42.SGD","LU1894683264.USD","LU2237438978.USD","GOOGL","BK4573","LU1232071149.USD","LU1720051108.HKD","LU1880398554.USD","LU0784385840.USD","LU2430703251.USD","LU0215105999.USD","LU2092937148.SGD","LU0276348264.USD","LU2491050154.USD","LU2089283258.USD","LU2456880835.USD","LU1244550494.USD","LU1267930730.SGD","LU1066051225.USD","CME","LU0097036916.USD","LU2362540622.SGD","LU1989772923.USD","IE00B7SZLL34.SGD","LU2404859667.USD","IE000WAW04H5.SGD","LU0348723411.USD","LU2097344431.USD","LU0690374615.EUR","LU0757428866.USD","LU0345770993.USD","LU0672654240.SGD","IE00B19Z9505.USD","LU2433249047.HKD","LU2491050071.SGD","BK4139","LU0211326839.USD","HK0000304805.HKD","LU2264538146.SGD","LU1116320901.HKD","LU1633808545.USD","LU2265009873.SGD","LU0320765059.SGD","GOOP","BK4533","LU1988902786.USD","LU0267386448.USD","LU2210149790.SGD","LU0138981039.USD","LU1366192091.USD","LU0208291251.USD","LU2860962120.EUR","LU1235294995.USD","LU2210150020.SGD","LU2191332357.HKD","LU1778281490.HKD","LU0426417589.USD","SG9999015986.USD","LU1066051811.HKD","LU1481011911.USD","LU0868494617.USD","LU0170899867.USD","BK4563","IE00BJLML261.HKD","IE00BQXX3C00.GBP","LU2505996509.AUD","DXCM","LU0316494557.USD","LU0128525689.USD","LU1923623000.USD","LU1951198990.SGD","LU1670627923.USD","LU1244550577.SGD","BK4538","LU0289960550.SGD","LU1145028129.USD","LU0256863902.USD","LU0158827948.USD","LU0234572021.USD","LU1435385759.SGD","LU2023250504.SGD","GOU","LU0124676726.USD","LU0006306889.USD","LU2471134796.USD","LU0312595415.SGD","LU2420271590.USD","LU1868836914.USD","LU2506951875.HKD","LU0130517989.USD","LU0345768740.USD","LU0130102774.USD","LU1868836591.USD","LU2087621335.USD","LU2168564222.USD","IE0001KFT4U8.USD","HK0000532082.HKD","LU2023250843.SGD","LU2065171402.SGD","LU1718418525.SGD","LU2491049909.HKD","LU2756315318.SGD","PLU","BK4579","LU0942090050.USD","LU1303367103.USD","LU0127658192.USD","LU2471134523.USD","LU0648001328.SGD","LU2054465674.USD","LU2244417387.USD","LU1481011671.HKD","LU1935042215.USD","LU0310800965.SGD","LU2275660780.HKD","LU2417539215.USD","LU0265550946.USD","LU0128525929.USD","SG9999014898.SGD","LU0823434583.USD","RGEN","IE00B19Z3581.USD","BK4585","LU1815336760.USD","BK4592","IE00BQXX3D17.EUR","IE00BN8TJ469.HKD","SG9999014906.USD","LU0106261612.USD","LU0708994859.HKD","LU2357305700.SGD","LU0158827781.USD","LU2362541513.USD","LU0477156797.USD","LU0976567544.SGD","LU1119994496.HKD","IE00BDGV0183.EUR","LU0742534661.SGD","BK4551","LU0211327993.USD","IE00B3PB1722.GBP","LU0342679015.USD","LU0048573561.USD","LU1046421795.USD","LU0820561818.USD","BK4574","LU1951200564.SGD","IE0034235303.USD","LU0640476718.USD","BK4504","LU1732800096.USD","LU1880398471.USD","LU0784384876.USD","LU1894683348.USD","LU1868837136.USD","LU1720051017.SGD","BK4112","LU0444973449.USD","BK4527","LU0795875086.SGD","LU0444971666.USD","LU0823417737.USD","LU1043141123.HKD","LU1803068623.USD","LU1496350171.SGD","IE0034235188.USD","LU0203347892.USD","LU1121112475.USD","LU0731783394.SGD","LU1221951129.SGD","LU2095319765.USD","LU0256863811.USD","LU0061474705.USD","LU0029864427.USD","GB00B4QBRK32.GBP","LU0210533765.USD","LU2168564149.EUR","IE000SO60NU8.SGD","LU1032955483.USD","LU0345774631.USD","LU2505996681.GBP","LU0964807845.USD","LU0149725797.USD","WGS","LU1400636657.SGD","LU1196500208.SGD","PL","LU0069063385.USD","IE0000B7K699.USD","LU0130103400.USD","BK4082","LU0157215616.USD","LU0211326755.USD","IE00BBT3K403.USD","BK4503","LU0642271901.SGD","LU0882574139.USD","BK4173","LU0943347566.SGD","IE00BMPRXN33.USD","LU1064131342.USD","IE00BKPKM429.USD","LU1585245621.USD","LU1989772840.SGD","LU2168564065.EUR","LU1629891620.HKD","LU0353189680.USD","LU2954938101.SGD","LU1674673428.USD","LU0823417653.USD","LU2746668974.SGD","LU1221951046.USD","SG9999017495.SGD","IE00BWXC8680.SGD","BK4532","LU0466842654.USD","LU2097344357.USD","LU1280957306.USD","LU0251142724.SGD","LIFE","LU1974910355.USD","LU2236285917.USD","LU0648000940.SGD","LU0957808578.USD","LU2381873111.SGD","BK4550","LU2430703178.SGD","IE00B1XK9C88.USD","LU0345774391.USD","LU0265550359.USD","LU1823568750.SGD","LU2125909247.SGD","LU1043141396.HKD","LU0820561909.HKD","LU0080751232.USD","IE0004091025.USD","SG9999018857.SGD","LU0957791311.USD","SG9999015945.SGD","LU0661504455.SGD","LU2087625088.SGD","GB00B4LPDJ14.GBP","BK4548","IE00BZ1G4Q59.USD","BK4121","IE00BKVL7J92.USD","LU0708995401.HKD","LU1599440770.SGD","LU2403377893.USD","IE00BVYPNW00.USD","LU1066053197.SGD","LU1868837300.USD","LU2471134952.CNY","SG9999014914.USD","LU2471134879.HKD","LU0545039389.USD","LU1496350502.SGD","LU2063271972.USD","LU2360106780.USD","LU1839511570.USD","LU0354030438.USD","LU1201861249.SGD","LU1914381329.SGD","LU1935042991.SGD","LU0792757196.USD","LU1201861165.SGD","LU1066051498.USD","LU1935043023.USD","LU0266013472.USD","IE0004086264.USD","IE00BFMHRM44.USD","IE00BJTD4N35.SGD","LU2168563687.JPY","LU0494093205.USD","LU1400636491.USD","LU0772969993.USD","LU2462157665.USD","BK4007","LU0175139822.USD","LU2168564495.EUR","LU1202635105.USD","LU2089284900.SGD","IE00BDRTCR15.USD","LU2125909593.SGD","LU1153585028.USD","BK4077","IE00BYXW3230.USD","LU2462591277.SGD","LU0061475181.USD","LU0731783048.USD","LU0096364046.USD","LU1116320737.USD","LU1551013425.SGD","LU1923622614.USD","LU0994945656.USD","IE00BMPRXQ63.HKD","LU2746668461.USD","LU2065171311.SGD","IE0034235295.USD","IE00BLSP4239.USD","SG9999018865.SGD","LU0143551892.USD","LU0949170426.SGD","LU1804176565.USD","LU0225283273.USD","LU0496365809.HKD","LU2242649171.HKD","LU0096362180.USD","LU2098885051.SGD","LU0323591593.USD","LU1571399168.USD","RVMD","LU1267930490.SGD","IE00BMPRXR70.SGD","LU0251131958.USD","IE000F7OJYX1.SGD","LU2023251221.USD","BK4514","LU0077335932.USD","LU2065169927.USD","LU0056508442.USD","IE00BK4W5M84.HKD","LU0889566641.SGD","SG9999015978.USD","LU1316542783.SGD","LU1935042488.USD","LU2247934214.USD","LU2125154778.USD","LU1868836757.USD","IE00BK4W5L77.USD","LU0557290698.USD","LU1429558221.USD","LU2125154935.USD","LU2326559502.SGD","PAYP","LU0130518102.USD","LU0203345920.USD","LU2097829019.USD","LU1059921491.USD","LU1267930813.SGD","LU2213496289.HKD","LU0980610538.SGD","IE00B19Z8W00.USD","LU0949170772.SGD","LU2242650005.HKD","BK4566","LU1366333091.USD","LU1642822529.SGD","IE00B1BXHZ80.USD","LU0320765489.SGD","IE00BSNM7G36.USD","LU0545562505.USD","LU0476273544.USD","LU1400636574.HKD","BK4588","BK4602","LU0787776722.HKD","LU0094547139.USD","LU0683600562.USD","IE000MB6IJN5.SGD","IE00B42XCP33.USD","GOOX","LU2404859741.USD","LU1228905540.USD","LU0345768153.USD","LU0052756011.USD","LU0061474960.USD","LU0823421333.USD","LU2250418816.HKD","LU1815333072.USD","LU0211328371.USD","LU0211331839.USD","LU2430703095.HKD","LU0070302665.USD","LU2065170008.USD","LU2592432038.USD","LU0784383803.USD","BK4123","LU0070217475.USD","LU0985320562.USD","BK4612","LU0742537680.HKD","IE00BVYPNV92.GBP","SG9999015952.SGD","LU0314106906.USD","LU0109391861.USD","LU0345770308.USD","LU0528227936.USD","BK4227","LU0472753341.HKD","LU1551013342.USD","LU1791710582.SGD","LU0048584097.USD","LU0289739343.SGD","LU2999663052.SGD","LU0784385170.HKD","GOOW","LU0310800379.SGD","LU0689472784.USD","IE00BHPRN162.USD","HK0000304797.USD","LU1228905037.USD","LU0820562030.AUD","LU1244550221.USD","LU1506573853.SGD","SGXZ99366536.SGD","BK4543","IE00BGHQF631.EUR","LU2362541273.HKD","BK4581","LU1815336091.USD","LU2506951958.HKD","LU0310799852.SGD","IE00B3T34201.USD","LU2133065610.SGD","LU1852331112.SGD","LU0345769631.USD","LU2462591350.SGD","LU1645745479.HKD","LU2360032135.SGD","SGXZ81514606.USD","LU1699723380.USD","LU2077746001.SGD","LU0912757837.SGD","GGLL","LU2506952097.USD","IE00BLSP4452.SGD","LU0417517546.SGD","SGXZ31699556.SGD","LU0426412945.USD","LU2092627202.USD","LU0011850046.USD","LU0345769128.USD","IE000M9KFDE8.USD","LU2023250330.USD","LU2750360997.AUD","LU1267930227.SGD","LU1670756490.USD","LU2211815571.USD","LU1732799900.SGD","LU2347655156.SGD","GGLS","LU1084165304.USD","LU0289961442.SGD","LU0477156953.USD","LU1548497426.USD","IE00BDCRKT87.USD","LU1509826696.USD","SG9999014880.SGD","LU2750360641.GBP","LU0353189763.USD","LU0868494708.USD","LU1301847155.USD","LU0154236417.USD","LU0057025933.USD","LU0690374961.EUR","LU0314104364.USD","LU0795875169.SGD","IE0002270589.USD","IE00BQXX3F31.USD","GOOY","BK4598","IE00BJTD4V19.USD","IE00BKDWB100.SGD","LU0689626769.HKD","LU0187121727.USD","LU2028103732.USD","LU1917777945.USD","LU1989764664.SGD","LU0234570918.USD","LU0251132253.USD","LU0302445910.USD","LU0198837287.USD","LU2602419157.SGD","LU0354030511.USD","LU0738911758.USD","LU1267930573.SGD","LU1323610961.USD","LU0012050646.USD","LU0106261372.USD","LU0950375773.USD","LU2106854487.HKD","BK4196","LU0174119429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164920364","title":"Revolution Medicines获FDA\"安全进行\"函，启动Daraxonrasib治疗胰腺癌的扩大用药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1164920364","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164920364?lang=zh_cn&edition=full","pubTime":"2026-05-01 23:51","pubTimestamp":1777650678,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已向Revolution Medicines, Inc.发出\"安全进行\"函，批准启动其候选药物Daraxonrasib针对胰腺癌患者的扩大用药治疗方案。\n该函件的获得意味着Revolution Medicines可以开始为符合条件的胰腺癌患者提供这种实验性治疗药物。扩大用药方案旨在让尚未参与临床试验的患者能够获得有前景的研究性疗法。\nDaraxonrasib是Revolution Medicines研发的一种靶向治疗药物，此次获批的扩大用药方案将为胰腺癌患者提供新的治疗选择。这一进展标志着该药物在临床开发道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179777848","title":"异动解读 | Revolution Medicines盘中大涨9.91%，受积极临床数据及竞争对手安全事件提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1179777848","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179777848?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:35","pubTimestamp":1777383335,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.  今日盘中股价大涨9.91%，引起了市场的广泛关注。消息面上，公司此前在AACR会议上发布的胰腺癌新药daraxonrasib积极临床数据构成了基本面的重要支撑。尽管Erasca的药物在试验中显示出较高的肿瘤反应率，但此次安全事件引发了市场对竞争对手的担忧。有分析指出，在同一试验中，Erasca药物的疗效数据优于Revolution Medicines的竞争药物daraxonrasib，但RBC资本市场认为，Revolution Medicines在RAS治疗领域仍保持着明显的领先地位。市场情绪的对比可能进一步推动了资金流向被视为更安全的标的Revolution Medicines。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124949914","title":"Revolution Medicines完成同步增发募资约22亿美元 承销商超额配售权全额行使","url":"https://stock-news.laohu8.com/highlight/detail?id=1124949914","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124949914?lang=zh_cn&edition=full","pubTime":"2026-04-18 04:03","pubTimestamp":1776456191,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc. (RVMD)宣布已完成同步扩大规模的公开发行，总募资金额约达22亿美元。此次发行包含承销商全额行使超额配售权购入的额外股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186662574","title":"异动解读 | 宣布20亿美元增发计划，Revolution Medicines盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186662574","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186662574?lang=zh_cn&edition=full","pubTime":"2026-04-16 03:01","pubTimestamp":1776279666,"startTime":"0","endTime":"0","summary":"生物技术公司Revolution Medicines, Inc.  今日盘中股价大幅上涨5.18%，引起了市场的广泛关注。消息面上，该公司于今日宣布对其同步进行的普通股和可转换优先票据公开发行进行定价，将融资总额大幅上调至约20亿美元。同时，公司还将发行总额5亿美元、2033年到期、年利率0.50%的可转换优先票据，该规模也由原计划的2.5亿美元实现翻倍。此外，市场亦关注该公司与Tango Therapeutics在抗癌药物vopimetostat上的合作进展。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627289764","title":"Revolution Medicines(RVMD)宣布定价20亿美元增发：含普通股与可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289764","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627289764?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:36","pubTimestamp":1776253004,"startTime":"0","endTime":"0","summary":"本次普通股和票据的发行预计将分别于2026年4月16日和4月17日完成交割，两项发行的完成互不作为前提条件。可转换优先票据方面：公司同步发行总额为5亿美元、2033年到期、年利率为0.50%的可转换优先票据。其初始转换价格约为每股198.80美元，较本次普通股发行价溢价约40.0%。本次两项发行规模均大幅上调，预计募资总额高达约20亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NDc2NDdkNmE3OTQ1ODAzNzE4MGUxMjI3MTI4NzA1NDk3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDc2NDdkNmE3OTQ1ODAzNzE4MGUxMjI3MTI4NzA1NDk3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142978648","title":"Revolution Medicines提交SEC文件：计划发行1060万股普通股及5亿美元可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1142978648","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142978648?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:14","pubTimestamp":1776248067,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件显示，Revolution Medicines, Inc.正式启动融资计划。该公司拟公开发行1060万股普通股，同时发行总规模达5亿美元的可转换优先票据。\n此次融资方案将结合股权与债权工具，凸显企业多元化资本运作策略。可转换票据的发行将为投资者提供债转股选择权，进一步拓宽公司资本补充渠道。市场分析认为，此举或为后续研发管线推进及业务扩张储备资金动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108861803","title":"Revolution Medicines, Inc. 完成总额20亿美元普通股及可转换优先票据同步增发定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1108861803","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108861803?lang=zh_cn&edition=full","pubTime":"2026-04-15 12:42","pubTimestamp":1776228134,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc. 已成功为其同步进行的增发交易完成定价，此次发行包括普通股及可转换优先票据，募集资金总额高达20亿美元。该交易规模较最初计划有所扩大，显示出市场对其融资方案的强劲需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441319","title":"Revolution Medicines胰腺癌药物取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441319","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627441319?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:09","pubTimestamp":1776172140,"startTime":"0","endTime":"0","summary":"Revolution Medicines表示，daraxonrasib在既往接受过治疗的胰腺癌中达到了3期临床试验终点，将中位总生存期延长一倍至13.2个月（化疗组为6.7个月），并计划寻求FDA审查。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-14/doc-inhunpmv9018109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118425869","title":"Revolution Medicines盘后股价下跌1.6% 宣布拟公开发行普通股及可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1118425869","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118425869?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:20","pubTimestamp":1776111643,"startTime":"0","endTime":"0","summary":"生物制药公司Revolution Medicines, Inc.在收盘后交易时段股价下挫1.6%，同时宣布将启动普通股与可转换优先票据的发行计划。此次融资举措旨在为公司的研发管线提供资金支持，特别是针对其创新肿瘤靶向疗法的临床开发。市场分析师指出，此类融资行为通常会对短期股价形成压力，但长期来看有助于推动企业核心业务发展。公司尚未披露具体发行规模与定价条款，但表示将根据市场条件适时推进发行工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":0.1245},{"period":"3month","weight":0.2953},{"period":"6month","weight":0.5427},{"period":"1year","weight":3.7707},{"period":"ytd","weight":1.3012}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.003651},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}